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Alpha-synuclein is a presynaptic protein expressed throughout the central nervous
system, and it is the main component of Lewy bodies, one of the histopathological
features of Parkinson’s disease (PD) which is a progressive and irreversible
neurodegenerative disorder. The conformational flexibility of α-synuclein allows it to adopt
different conformations, i.e., bound to membranes or form aggregates, the oligomers
are believed to be the more toxic species. In this review, we will focus on two major
features of α-synuclein, transmission and toxicity, that could help to understand the
pathological characteristics of PD. One important feature of α-synuclein is its ability to
be transmitted from neuron to neuron using mechanisms such as endocytosis, plasma
membrane penetration or through exosomes, thus propagating the Lewy body pathology
to different brain regions thereby contributing to the progressiveness of PD. The second
feature of α-synuclein is that it confers cytotoxicity to recipient cells, principally when it is
in an oligomeric state. This form causes mitochondrial dysfunction, endoplasmic reticulum
stress, oxidative stress, proteasome impairment, disruption of plasma membrane and
pore formation that lead to apoptosis pathway activation and consequent cell death. The
complexity of α-synuclein oligomerization and formation of toxic species could be a major
factor for the irreversibility of PD and could also explain the lack of successful therapies to
halt the disease.
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GENERAL OVERVIEW
Misfolded proteins are rich in β-sheet structure with a high ten-
dency to form long fibrillar aggregates known as amyloid deposits
(Soto, 2012). Amyloid is a generic term referring to organized
protein aggregates with specific staining properties, higher resis-
tance to proteolytic degradation and a fibrillar appearance when
observed with electronic microscopy (Soto, 2003). β-structures
are harder to degrade than α-helixes (main conformation of
native proteins), which explains why amyloid deposits cannot
be removed by the proteasome system (Lee and Yu, 2005). The
aggregation of misfolded proteins is believed to occur when
hydrophobic residues exposed at the surface of proteins interact
with other misfolded proteins (Doyle et al., 2011).
There is a group of neurodegenerative diseases characterized
by the misfolding of proteins into β-sheet aggregated structures
Abbreviations: Aβ, amyloid beta; α-syn, alpha synuclein; A30P, alanine 30 pro-
line; A53T, alanine 53 threonine; AD, Alzheimer’s disease; DA, dopamine; E46K,
glutamic acid 46 lysine; ER, endoplasmic reticulum; ERS, endoplasmic reticulum
stress; Grp 78, glucose-regulated protein 78; Grp 94, glucose-regulated protein
94; LB, Lewy body; L-dopa, L-dihydroxyphenylalanine; LN, Lewy neurite; PD,
Parkinson’s disease; PDI, protein disulfide isomerase; PFF, preformed fibrils; PrP,
prion protein; PrPC, cellular prion protein; PrPSC, scrapie prion protein; pS129-
α-syn, α-syn phosphorylated at serine 129; ROS, reactive oxygen species; Ser129,
serine 129; SNARE, soluble N-ethylmaleimide-sensitive factor attachment protein
receptor; SNpc, substantia nigra pars compacta; Tg, transgenic; TKO, triple knock-
out; TNT, tunneling nanotubes; UPR, unfolded protein response; WGA, wheat
germ agglutinin; WT, wild type.
that accumulate as amyloid deposits in affected tissues (Moreno-
Gonzalez and Soto, 2011). These conformational disorders or
protein misfolding diseases include Alzheimer’s disease (AD)
with extracellular plaques of amyloid-β protein (Aβ) and tan-
gles of hyperphosphorylated tau protein in the cytoplasm of
neurons; Parkinson’s disease (PD) where the cytoplasm of neu-
rons in the substantia nigra contains aggregates called Lewy
bodies composed principally of the protein α-synuclein (α-syn);
Huntington’s disease; Amyotrophic Lateral Sclerosis; and trans-
missible spongiform encephalopathy characterized by an accu-
mulation of aggregates of the prion protein (PrP) in the brain
(Soto, 2003).
Prion proteins propagate by auto-catalytic conversion of
native, nonpathogenic forms of the protein (PrPC) expressed in
several types of human cells (Frost and Diamond, 2010), into
misfolded pathological conformation (PrPSc) (Moreno-Gonzalez
and Soto, 2011; Costanzo and Zurzolo, 2013). In prion disease,
the pathological conformation is the primary infectious agent
(Soto and Satani, 2011; Munch and Bertolotti, 2012) that propa-
gates using a mechanism called “seeding/nucleation” where PrPSc
acts like a seed that recruits and converts soluble protein into
aggregates of PrPC which form polymers (Moreno-Gonzalez and
Soto, 2011; Munch and Bertolotti, 2012). As prions grow and
spread, they interfere with the function of the nervous system
resulting in progression of the disease in affected patients (Jucker
and Walker, 2013).
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Accumulating experimental data indicate that the seeding
principle, similar to the conversion of PrPC to PrPSc in prion
diseases, also applies to other proteins associated to neurodegen-
erative diseases such as AD and PD (Soto, 2012; Costanzo and
Zurzolo, 2013; Jucker and Walker, 2013). In this review, we will
address features of the α-syn protein that propagates and causes
toxicity in recipient neurons, which could explain the progressive
and irreversible pathology of PD.
PARKINSON’S DISEASE
Parkinson’s disease (PD) is the second most common neurode-
generative disease after AD (Feng et al., 2010). The two patholog-
ical hallmarks of PD are the presence of cytoplasmic inclusions
termed Lewy bodies and Lewy neurites, and the selective degen-
eration and loss of dopaminergic neurons in the substantia nigra
pars compacta (SNpc) (Smith et al., 2005; Luk et al., 2012a) lead-
ing to the main motor symptoms of PD, i.e., resting tremor,
muscle rigidity, bradykinesia, and postural instability (Jankovic,
2008; Feng et al., 2010; Luk et al., 2012b). For this reason, PD is
generally defined as a movement disorder associated with degen-
eration of neurons in the nigrostriatal system (Desplats et al.,
2009). The diagnosis of PD relies mainly on the clinical detection
of these motor symptoms, but there is no definitive diagnostic
test. The symptoms are often accompanied by the appearance
of autonomic, cognitive and psychiatric problems (Mercuri and
Bernardi, 2005; Jankovic, 2008).
During the early stages of the disease, called the presymp-
tomatic phase, PD patients develop non-motor deficits includ-
ing olfaction impairment, vagal dysfunction and sleep disorders
(Angot and Brundin, 2009). The typical motor symptoms appear
when there is 50–60% of dopaminergic neuron loss and 70–80%
of dopamine depletion (Schapira, 2009; Sato et al., 2013). The
cognitive functions decline at more advanced stages (Angot and
Brundin, 2009). As a result of these clinical symptoms, PD is now
recognized as a complex clinicopathological entity. The presence
of cognitive impairment or dementia in patients with PD is asso-
ciated with loss of independence, a lower quality of life and a
reduction in survival time (Irwin et al., 2013). The majority of
PD cases are sporadic (Feng et al., 2010) and the etiology and
pathogenesis remain enigmatic (Brundin et al., 2008). The ori-
gin and development of the disease seems to involve both genetic
susceptibility and environmental factors such as oxidative stress,
proteasome inhibition, and aging (Ross and Poirier, 2004; Smith
et al., 2005).
PATHOLOGICAL FINDINGS
The pathological hallmark of PD is the presence of intraneuronal
proteinaceous inclusions called Lewy bodies (LBs) or Lewy neu-
rites (LNs) depending if they are localized in the cell body or
the processes, respectively (Angot and Brundin, 2009). LBs are
spherical eosinophilic cytoplasmic protein aggregates that con-
tain ubiquitin and fibrils of α-syn, located in the substantia nigra
and in several central nervous system structures (Bisaglia et al.,
2009; Soto, 2012). The main protein component of LBs is α-syn,
a synaptic protein with the propensity to misfold and aggregate
(Angot et al., 2012). Analysis of these inclusions with immunohis-
tochemistry techniques revealed that they have affinity to specific
dyes that identify misfolded α-syn, such as Thioflavin S that rec-
ognizes β-sheet conformations, and for α-syn phosphorylated on
serine 129 (Ser129), which is a post-translational modification
that only occurs in LBs (Angot and Brundin, 2009). In PD, the
accumulation of Lewy bodies undergo an ascending pattern of
progression, spreading from the lower brainstem and olfactory
bulb into the limbic system and, eventually, to the neocortex,
suggesting a propagation mechanism similar to prion diseases
(Desplats et al., 2009).
PD IS PROGRESSIVE AND IRREVERSIBLE
There are two major features that identify PD: (1) progressive
damage of dopaminergic neurons in the SNpc that leads to
the depletion of dopamine (DA) release necessary to maintain
essential functions (Mercuri and Bernardi, 2005), and (2) the
appearance of non-motor symptoms associated to the degener-
ation of non-dopaminergic systems (Obeso et al., 2010) together
with propagation and accumulation of Lewy bodies in different
brain regions (Ross and Poirier, 2004; Desplats et al., 2009; Obeso
et al., 2010) making PD an irreversible, and at the present, an
incurable disorder (Singh et al., 2007).
Current pharmacological treatment for PD involves the use of
the dopamine precursor L-3,4-dihydroxyphenylalanine (L-dopa)
which alleviates bradykinesia, the increase in muscle tone and
tremor, but does not reduce non-motor symptoms (Mercuri and
Bernardi, 2005). DA agonists, COMT, and MAO-B inhibitors
are also used as adjunctive treatment to L-dopa (Schapira,
2009; Tarazi et al., 2014). In addition, the efficiency of L-dopa
decreases over time and many patients develop motor fluctu-
ations (wearing-off and on–off phenomena), dyskinesias and
behavioral abnormalities (Mercuri and Bernardi, 2005; Singh
et al., 2007; Obeso et al., 2010). Newer non-pharmacological
therapies include the use of viral vector genes to silence defec-
tive genes associated with PD. Surgical interventions such as
deep brain stimulation, pallidotomy, and thalamotomy, or non-
invasive procedures such as gamma knife radiation are also
employed (Tarazi et al., 2014). The available pharmacological
and non-pharmacological treatments focus primarily on motor
symptoms, but do not modify the progression of DA neuronal
degeneration in the SNpc or the other affected areas (Mercuri and
Bernardi, 2005; Singh et al., 2007; Tarazi et al., 2014).
ALPHA-SYNUCLEIN
STRUCTURE
Alpha-synuclein (α-syn) is a small, acidic protein of 14.5 kDa and
140 amino acids (Bisaglia et al., 2009) that is highly conserved in
vertebrates and is expressed in presynaptic nerve terminals in sev-
eral regions of the brain (Jain et al., 2013). The protein belongs to
the synuclein family, α-, β- and γ-synuclein, from three highly
expressed human genes (SNCA, SNCB, and SNCG) (Lavedan,
1998). The β-isoform also exhibits a presynaptic location and
co-localizes with α-syn at many, but not all presynaptic termi-
nals, whereas γ-synuclein is expressed by glia cells and specific
neuronal populations, mainly dopamine neurons (Bendor et al.,
2013). α-syn lacks a defined secondary structure and therefore
belongs to the intrinsically unstructured protein family (Bisaglia
et al., 2009; Deleersnijder et al., 2013). However, the remarkable
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conformational plasticity of α-syn allows it to adopt a wide
range of dynamic structures depending on the environment and
binding partners (Jain et al., 2013).
Figure 1A illustrates the three distinct regions of α-syn. (1)
The amino-terminal sequence of α-syn (residues 1–60) contains
variants of an imperfect 11 amino acid repeat with a highly con-
served hexamer motif similar to that found in the amphipathic
helices of apolipoproteins (Bellucci et al., 2012; Deleersnijder
et al., 2013). This portion of the protein includes the A30P, A53T,
and E46K mutation sites found in familial PD cases (Bisaglia
et al., 2009). (2) The central region (residues 61–95) termed NAC
(non-amyloid-β component) contains two additional motifs and
is the most hydrophobic portion of the protein. This region can
undergo a conformational change from a random coil to β-sheet
structure and is able to form cylindrical β-sheets and amyloid-
β-like fibrils (Bellucci et al., 2012; Deleersnijder et al., 2013).
(3) The carboxy-terminal of α-syn (residue 96–140) is rich in
acidic residues (Bisaglia et al., 2009) and is responsible for the
intrinsically disordered nature of α-syn. This region also plays
a regulatory role in the aggregation and fibril formation of the
protein (Deleersnijder et al., 2013). Dopamine can interact non-
specifically with the C-terminal residues of α-syn, suggesting that
inappropriate C-terminal cleavage of this protein, which is known
to occur in PD brains, might affect DA homeostasis (Bisaglia et al.,
2009; Bellucci et al., 2012).
Phosphorylation is one of the most common posttranslational
modifications and has a role on the function of numerous target
proteins (Sato et al., 2013). Thus, α-syn phosphorylated in Ser129
(pS129-α-syn) may have some functions in the normal brain.
Residue Ser129 in the C-terminal region of α-syn is approximately
90% phosphorylated in Lewy Bodies (Figure 1A). This form is
biochemically detectable in cerebral cortex, substantia nigra and
nucleus basalis of Meynert in normal human subjects (Walker
et al., 2013). Interestingly, no more than 4% of α-syn is phospho-
rylated at this residue in normal brain suggesting a strict control.
The phosphorylation of Ser129 is controlled by kinases, phos-
phatases, and degradation pathways (Hara et al., 2013; Sato et al.,
2013). Several studies identified the kinases responsible for the
phosphorylation of α-syn in vitro and in vivo, such as Polo-like
kinase PLK2 and PLK3, casein kinase CK1 and CK2 andmembers
of the G protein-coupled receptor kinase family GRK2, GRK3,
GRK5, and GRK6 (Hara et al., 2013; Sato et al., 2013; Kosten et al.,
2014). Phosphoprotein phosphatase 2A (PPA2) might be respon-
sible for dephosphorylation of α-syn, and stimulating the activity
of PP2A resulted in reduced levels of pS129-α-syn and aggregated
α-syn (Sato et al., 2013; Walker et al., 2013).
In vitro studies suggest that α-syn interacts with lipid mem-
branes through its repeat motifs and with small unilamellar
vesicles and micelles preferentially containing negatively charged
head groups (Ulmer et al., 2005). When α-syn interacts with
vesicles or membranes, the N-terminal of the protein acquires
an α-helical conformation that can be an extended helix or
antiparallel helices connected by a short linker, depending on
the membrane properties. The C-terminal of the protein remains
unstructured, as observed in Figure 1B (Ulmer et al., 2005;
Plotegher et al., 2014). The binding of α-syn to phospholipid
micelles produces a flattening in their surface curvature. In
addition, the α-syn mutants A53T and E46K exhibit increased
membrane-binding affinity and also flatten micelle surface curva-
ture, whereas the A30P α-syn mutant has a decreased membrane
FIGURE 1 | (A) Schematic representation of α-synuclein regions. The
amino-terminal from amino acids 1–60 is an amphipathic region responsible
for α-syn-membrane interactions. It contains repeats of hexamer motifs
similar to apolipoproteins (represented in the figure as red rectangles). The
point mutations of α-syn are located in this region (A30P, E46K, and A53T).
The central region from amino acids 61-95, termed NAC (non-β amyloid
component), is the most hydrophobic portion of the protein and is required
for the aggregation process. This region folds into a β-sheet secondary
structure and forms amyloid fibrils. The C-terminal from amino acids
96–140 is characterized by the presence of acidic residues and several
negative charges. The residue serine 129 in this region is phosphorylated
in Lewy bodies (Modified from Plotegher et al., 2014). (B) Schematic
representation of micelle-bound α-synuclein. The N-terminal region with
antiparallel α-helices is shown in blue, the NAC region is also an α-helix
and is shown in orange, and the unstructured C-terminal part is shown in
red. Numbers refer to amino acid residues. (Modified from Lashuel et al.,
2013). Reprinted by permission from MacMillan Publishers Ltd (Nature
Reviews Neuroscience).
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affinity and does not alter the surface curvature of the micelles
(Auluck et al., 2010).
PHYSIOLOGICAL ROLES
Studies suggest that α-synuclein is involved in the control of
synaptic membrane processes (Bellucci et al., 2012) and partici-
pates in the control of neurotransmitter release via interactions
with members of the SNARE family (Tsigelny et al., 2012). More
specifically, α-syn promotes SNARE-complex assembly through
a non-enzymatic mechanism, binding to phospholipids via its
N-terminal and to synaptobrevin-2 via its C-terminal (Burre
et al., 2010). However, the precise physiological functions of α-syn
remain uncertain and studies are often conflicting (Luk et al.,
2009). Individual synuclein knockout animals (α-, β- or γ-syn)
are viable (Lashuel et al., 2013) and results obtained in α-syn
knockout mice suggest that α-syn is not essential for synapse for-
mation or cell survival (Bisaglia et al., 2009) as supported by the
relatively late translocation of α-syn into presynaptic terminals
during synaptogenesis (Chandra et al., 2004).
The existence of three synuclein isoforms and the high degree
of co-expression of α- and β-syn raises the possibility of redun-
dant synaptic functions (Chandra et al., 2004; Greten-Harrison
et al., 2010). Analysis of α-/β-synuclein double knockout mice did
not showmajor changes in synaptic functions such as neurotrans-
mitter release, synaptic vesicle numbers, or synaptic plasticity,
and caused no structural abnormalities in the overall brain mor-
phology. However, the α-/β- double knockout did show a modest
reduction in striatal DA levels (Chandra et al., 2004; Bendor et al.,
2013), and it has been reported that α-syn binds to C-terminal of
the DA transporter increasing the DA uptake (Hara et al., 2013).
The triple synuclein knockout mice (TKO) were viable and fer-
tile, but developed severe neurological impairments resulting in a
striking age-dependent survival deficit ending in premature death
(Burre et al., 2010; Greten-Harrison et al., 2010). Furthermore,
the TKO mice exhibited an age-dependent decrease in SNARE-
complex assembly. Thus, synucleins are required for maintaining
normal SNARE-complex assembly during aging in mice (Burre
et al., 2010), and they are also relevant for long-term survival
(Greten-Harrison et al., 2010).
PATHOLOGICAL ROLES
The pathological roles of α-syn arise from the intracellular accu-
mulation of α-syn amyloid fibrils that define a family of neu-
rological disorders termed α-synucleinopathies in which PD is
included (Luk et al., 2009; Danzer et al., 2012). α-syn is able to
form oligomers, fibrils and large aggregates following overexpres-
sion, exposure to changes in pH, oxidative stress, or by interaction
with dopamine (Feng et al., 2010). Unlike α-syn, β-syn does not
fibrillize and both β- and γ-syn can inhibit the aggregation of
α-syn in vitro and in vivo (Bendor et al., 2013). Several post-
translational covalent modifications of α-syn have been described
to promote the pathological changes in the protein, including
serine and tyrosine phosphorylation, ubiquitination, nitration
and C-terminal truncation (Ross and Poirier, 2004; Deleersnijder
et al., 2013). The predominant modification of α-syn in Lewy
bodies is single phosphorylation at Ser129. However, the rela-
tionship between Ser129 phosphorylation and α-syn aggregation
remains unclear (Sato et al., 2013). Histopathological studies
of human brain show that increased levels of pS129-α-syn are
present in soluble and detergent insoluble brain fractions of
Lewy Body pathology. Thus, phosphorylation and ubiquitination
presumably increase aggregation and formation of an insoluble
fraction. As the α-syn solubility decreases, phosphorylation seems
to increase even more (Walker et al., 2013).
Mutations in the gene encoding α-syn (SNCA) directly link
α-syn with the onset of PD (Plotegher et al., 2014). The over-
expression of α-syn due to duplication or triplication of the
SNCA gene causes rare familial forms of parkinsonism, and sin-
gle nucleotide polymorphisms in the SNCA gene (Ala53Thr,
Ala30Pro, and Glu46Lys) are linked to sporadic PD (Angot et al.,
2012). Recently, new mutations have also been found in the N-
terminal part of the protein (Deleersnijder et al., 2013). The
three most common PD-related point mutations have shown
to accelerate α-syn aggregation (but not necessarily fibril for-
mation) in vitro. These effects can be explained by changes in
net charge, hydrophobicity, and secondary structure propensity
(Deleersnijder et al., 2013). This suggests that α-syn is heavily
implicated in the pathogenesis of PD, both familial and sporadic
cases (Smith et al., 2005; Angot et al., 2012).
CRITICAL FEATURES OF α-SYN FAVORING ITS TRANSMISSION AND
NEUROTOXICITY
Cellular transmission
Autopsy reports of PD patients who received bilateral intrastri-
atal grafts from healthy embryonic mesencephalic dopaminergic
neurons, 10–22 years before the postmortem analysis (Li et al.,
2008), showed that some of the grafted neurons contained patho-
logical α-syn or Lewy bodies similar to those observed in the host
brain (Li et al., 2008; Angot et al., 2012). These studies reported
that the LB and LN developed in the grafted neurons were ubiq-
uitinated, positive for Thioflavin S staining, and that α-syn was
phosphorylated on Ser129 indicating that it was aggregated, post-
translationally modified and disease-related (Brundin et al., 2008;
Li et al., 2008; Angot and Brundin, 2009). It was also found that
the α-syn accumulation in grafted neurons was time-dependent
(Brundin et al., 2008). The presence of pathology in the grafted
neurons could have been triggered by misfolded α-syn in the host
brain, which was transmitted into grafted cells with subsequent
seeding of aggregates in the recipient cells (Li et al., 2008). These
findings suggest that α-syn pathology propagates by a mechanism
similar to prion diseases (Hansen et al., 2011). For this reason,
numerous studies have attempted to replicate and explain these
findings in cell and animal models (Angot et al., 2012).
The introduction of exogenously assembled α-syn fibrils
to various cells overexpressing α-syn catalyzed intracellular
α-syn aggregation. The α-syn fibrils recruited endogenous sol-
uble α-syn, converting them into misfolded detergent-insoluble
inclusions which were hyperphosphorylated and ubiquitinated,
resembling Lewy bodies (Luk et al., 2009). In another study, a
specific type of α-syn oligomer was capable of inducing α-syn
seeding and aggregation after exogenous application to a neurob-
lastoma cell line and primary cortical neurons. This aggregation
process was dose- and time-dependent (Danzer et al., 2009). An
in vivo study showed that human α-syn expressed in mice was
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transmitted from cells in the brain to dopaminergic neurons
grafted into the striatum, in analogy to the mechanism suggested
to take place in the grafted PD cases previously mentioned (Angot
et al., 2012). The presence of Lewy bodies in grafted neurons was a
time-dependent process, with a higher percentage of neurons dis-
playing Lewy bodies in older grafts than in younger transplants
(Angot et al., 2012).
Studies with injected homogenates prepared from brainstem
and spinal cord of aged symptomatic animals that contained
abundant LB-like pathology, or with preformed fibrils (PFF)
assembled from human α-syn, into the neocortex and striatum
(Luk et al., 2012a) showed that despite the fact that inocula-
tions were unilateral, intraneuronal α-syn deposits were widely
distributed bilaterally and present throughout the CNS. This
indicated that α-syn pathology expanded through the CNS in a
time-dependent manner and accelerated the disease in vivo (Luk
et al., 2012b). Another study with non-transgenic mice (WT)
that were injected unilaterally with PFFs of α-syn in the striatum
showed that deposits of hyperphosphorylated α-syn were visible
at the injection site and several areas directly interconnected to
the striatum (Luk et al., 2012b). The contralateral neocortex also
developed LBs, revealing once again a time-dependent dissemina-
tion of these inclusions. The striatal inoculation led to abundant
α-syn pathology in neurons located in the SNpc. This was accom-
panied by the gradual loss of tyrosine hydroxylase immunore-
activity, suggesting that intraneuronal α-syn inclusions lead to
neurodegeneration and DA neuronal loss. In summary, this study
demonstrated that a single intrastriatal injection of synthetic mis-
folded α-syn into WT mice induced a neurodegenerative process,
with accumulation of intracellular LB/LN pathology, selective loss
of SNpc neurons, and impaired motor coordination (Luk et al.,
2012a).
Cellular transmission mechanisms
Lewy Body propagation within the CNS could be associated with
cell-to-cell transmission that involves the release of misfolded
α-syn from donor cells into the extracellular space. Recipient cells
could then take up the misfolded α-syn which recruits native
unfolded α-syn from the cytosol of the recipient cell and acts
as a template for the development of aggregates that eventually
lead to the formation of Lewy Bodies (Angot and Brundin, 2009;
Steiner et al., 2011). Studies have shown that cells can release
α-syn into their surroundings. For example, nanomolar concen-
trations of extracellular monomeric and oligomeric α-syn have
been detected in cerebrospinal fluid and plasma samples from
both PD patients and controls (El-Agnaf et al., 2006; Bellucci
et al., 2012; Costanzo and Zurzolo, 2013), with a significantly
higher concentration in PD patients (El-Agnaf et al., 2006) sup-
porting the occurrence of a secretory process for α-syn (Bellucci
et al., 2012).
Several transmission mechanisms have been reported for α-
syn (see Figure 2). For example, SH-SY5Y cells release α-syn
and its mutant variants A53T and A30P into the extracellular
space. The secretion is considerably reduced at 18◦C, suggesting
that α-syn is released from these cells via exocytosis (Lee et al.,
2005). However, Brefeldin A, a classical inhibitor of ER/Golgi-
dependent secretion, does not block α-syn release indicating that
α-syn exocytosis relies on an unconventional secretory pathway
(Lee et al., 2005; Angot and Brundin, 2009; Costanzo and Zurzolo,
2013). Neuronal cells subjected to various stress conditions
including oxidative stress and proteolytic impairment increase the
translocation of α-syn into vesicles and the release of monomeric
and aggregated α-syn (Jang et al., 2010). Failure of intracellu-
lar clearance pathways, such as autophagy, could also contribute
to the pathological release of α-syn increasing its transfer to
FIGURE 2 | Cell-to-cell transmission mechanisms of α-synuclein. (1)
Exosomes are small membrane vesicles derived from the endocytic
pathway, and the presence of α-syn inside exosomes and its transmission
to recipient cells has been reported. (2) α-syn could be released through
an exocytosis process and accumulate in the extracellular space and be
taken up by other cells through endocytosis. (3) α-syn associates to
biological membranes by its N-terminal, penetrates the membrane and
gains access to the cytosol. (4) Tunneling nanotubes are membrane
bridges of actin between cells, but this mechanism has not been
identified to participate in α-syn transmission. (5) Dying cells could be an
important reservoir of pathological α-syn when they eventually expel their
contents after being lysed.
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other cells (Lee et al., 2013). The release of pathogenic α-syn
from dying cells [see Figure 2(5)] could also contribute to the
extracellular pool of α-syn in the brain (Angot and Brundin,
2009). It has been reported that α-syn moves antero- and ret-
rogradely along axons (Steiner et al., 2011). For example, α-syn
fibrils could be internalized, anterogradely transported within
axons, released, and subsequently taken up by additional neu-
rons (Freundt et al., 2012). Recently, tunneling nanotubes (TNTs)
have been proposed to be involved in intercellular propagation of
PrPSc. As observed in [Figure 2(4)], TNTs are actin-containing
membrane bridges between cells (Angot and Brundin, 2009)
acting as conduits for the exchange of cytosolic and membrane-
bound molecules and organelles, as well as for the spreading of
pathogens (Costanzo and Zurzolo, 2013). TNTs have not yet been
implicated in other neurodegenerative diseases, or the spreading
of other misfolded proteins such as α-syn (Angot and Brundin,
2009).
Membrane penetration. Several studies have shown that the 11-
amino acid imperfect repeats of α-syn play a critical role in the
cell membrane translocation of α-syn. This uptake process is not
inhibited when Chinese hamster ovary cells were incubated at a
low temperature (4◦C), suggesting that receptor-mediated endo-
cytosis is not involved. In addition, the uptake of α-syn is insen-
sitive to treatment with the general exo/endocytosis inhibitors
Brefeldin A and Cytochalasin D (Ahn et al., 2006). A study using
computer modeling and membrane simulations investigated the
course of penetration ofWT and A53Tmutant α-syn in themem-
branes and pore formation activity. Their data showed that the
N-terminal initially makes contact with the surface of the mem-
brane, undergoing changes in secondary structure, and that the
penetration of the A53T mutant α-syn across the membrane was
20% faster than WT α-syn (Tsigelny et al., 2012).
Exosomes. Exosomes have been proposed to participate in the
spreading of disease-related proteins within the brain, such as
PrPSc in prion diseases and β-amyloid peptide (Aβ) in AD.
Exosomes are small membrane vesicles derived from the endo-
cytic pathway and are released from cells into the surroundings.
A wide range of cells secrete exosomes in vitro, including neu-
rons and astrocytes (Angot and Brundin, 2009). For this reason,
Danzer et al. (2012) investigated whether oligomeric species of
α-syn are present in exosomes. The authors provided evidence
that α-syn oligomers are indeed present in the exosomal frac-
tions from both neuronal and non-neuronal cells. According to
their results, exosome-associated α-syn oligomers are more prone
to being taken up by cells than exosome-free α-syn oligomers
and confer more cytotoxicity when compared to the increase in
Caspase 3/7 activation (Danzer et al., 2012).
In another study, α-syn was also detected in exosomes of
cells overexpressing α-syn and transmitted to normal SH-SY5Y
cells. It has been reported that lysosomal function is decreased
in PD patients, and α-syn requires the lysosome for its degra-
dation. Thus, the investigators inhibited lysosomal function in
the exosome donor cells and the exosomal α-syn level increased
significantly, as well as the release of α-syn which led to greater
transmission to recipient cells and a greater number of cells
containing α-syn inclusions. The hypothesis of this group is that
lysosomal dysfunction can accelerate exosomal α-syn release and
propagation to neighboring cells with associated increase in α-syn
inclusion formation (Alvarez-Erviti et al., 2011).
Endocytosis. Another transmission mechanism of α-syn was
described in a study that used human dopaminergic neuronal
cells treated with α-syn. The cells take up α-syn and approx-
imately half of the inclusions formed in these cells displayed
ubiquitin immunoreactivity and were stained with thioflavin S,
resembling Lewy Bodies. Dynamin-1 K44A, a dominant neg-
ative mutant that blocks endocytic vesicle formation, reduced
significantly the transmission of α-syn, as compared to cells
not expressing this inhibitor. In addition, 90% of the transmit-
ted α-syn was colocalized with endosomal GTPases rab5a and
rab7 to further support endocytosis as a possible transmission
mechanism (Desplats et al., 2009).
A similar study reported the entry of α-syn from the con-
ditioned medium into SH-SY5Y cells. The α-syn uptake was
observed in cells incubated at 37◦C, but not in cells incubated
at 4◦C suggesting that α-syn could be taken up by endocyto-
sis. To validate this observation, cells were co-cultured with the
endocytosis inhibitors monodansylcadaverine or dynasore. These
inhibitors decreased the number of cells with α-syn inclusions,
indicating that endocytosis plays an important role in the α-syn
intercellular transfer. To determine whether endocytic mecha-
nisms were also involved in the uptake of α-syn in vivo, dynasore
was coinjected with α-syn monomers in the right neocortex of
rats. The data revealed that the α-syn signal was reduced by 40%
in the right cortex where the inhibitor was coinjected with α-syn,
suggesting that endocytosis contributes significantly to neuronal
uptake of α-syn both in vitro and in vivo (Hansen et al., 2011).
PFFs of α-syn also enter inside neurons and seed recruit-
ment of endogenous α-syn to initiate accumulation of pathologic
hyperphosphorylated α-syn. Treatment of neurons with α-syn
PFFs in the presence of wheat germ agglutinin (WGA) induced
adsorptive mediated endocytosis, which increased the extent of
α-syn pathology in a dose-dependent manner. The addition of
a competitive inhibitor of WGA reduced its effects on α-syn-
induced aggregate formation. Taken together, these findings indi-
cate that α-syn PFFs could gain access to the neuronal cytoplasm
by adsorptive endocytosis (Volpicelli-Daley et al., 2011).
Mechanisms of neurotoxicity of α-synuclein
Under pathological conditions, progressive accumulation of
α-syn and the formation of oligomers have been proposed to
play a critical role in the pathogenesis of PD and other α-
synucleinopathies (Tsigelny et al., 2012). However, there are still
unresolved issues according to the precise mechanisms through
which α-syn aggregation contributes to neurodegeneration, the
nature of the toxic forms of α-syn and the cellular pathways that
are affected by α-syn (Tsigelny et al., 2012; Lashuel et al., 2013).
The multifunctional properties of α-syn may lie in its confor-
mational flexibility, which allows the protein to change its confor-
mation upon interaction with biological membranes of different
compositions, other proteins or protein complexes (Lashuel et al.,
2013; Plotegher et al., 2014). Several factors including oxidative
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stress, long incubations at 37◦C, post-translational modifications,
the concentrations of fatty acids, phospholipids, and metal ions
(Fe2+, Cu2+, and Zn2+), or application of various ligands such
as dopamine have shown to induce and/or modulate α-syn struc-
ture and oligomerization in vitro (Lashuel et al., 2013). Numerous
studies show that the soluble oligomers have a higher cytotoxicity
compared to the fibrillar form of the protein (Stockl et al., 2013).
Several different toxic mechanisms have been associated to
the α-syn aggregation process and to its oligomeric and fibrillar
products. Due to the heterogeneity of the aggregation prod-
ucts, it is reasonable to find a large variety of noxious effects
attributed to α-syn (Plotegher et al., 2014). Similar to transmis-
sion, α-syn cytotoxicity may occur through different mechanisms.
See Figure 3.
Proteasome impairment and oxidative stress. One of the stud-
ies that evaluated α-syn toxicity found that the induction of
A53T α-syn expression in PC12 cells increased cell death in a
time-dependent manner (Smith et al., 2005). The expression
FIGURE 3 | Toxic mechanisms of α-synuclein and cell death. (1)
Proteasome impairment: inhibition of chymotryptic, tryptic and post-acidic
proteasome activity leading to further intracellular accumulation of
misfolded proteins such as α-syn. (2) Pore formation: α-syn oligomers
penetrate cellular membranes increasing the conductance by forming
pore-like structures that could act as non-selective channels, resulting in
abnormal calcium influx. (3) Mitochondrial dysfunction: α-syn associates to
the mitochondrial inner and outer membrane and (4) Increases
mitochondrial and intracellular ROS levels. (5) Release of cytochrome C:
accumulation of intramitochondrial ROS and Ca2+ leads to reduction in
mitochondrial membrane potential and opening of permeability transition
pores that could cause the release of cytochrome C to the cytosol. (6) RE
stress: cellular accumulation of misfolded proteins can lead to chronic
endoplasmic reticulum stress. α-syn associates to ER membrane and
causes morphologic dysfunction such as dilated cisternae and increases
the level of ER chaperones. (7) Cytochrome C leads to activation of
caspase-3 and -9, and ER stress leads to activation of caspase-12. (8)
Caspases initiate apoptosis leading to cell death.
of A53T α-syn inhibited chymotryptic, tryptic, and post-acidic
proteasome activity. Additionally, the expression of A53T α-syn
significantly increased the intracellular level of reactive oxygen
species (ROS). These results indicate that the expression of A53T
α-syn in PC12 cells caused early biochemical changes leading to
proteasome inhibition and oxidative stress (Smith et al., 2005).
The generation of ROS may cause oxidative neuronal damage.
The main source of ROS in nigral neurons is thought to be the
metabolism of dopamine itself. Another study using SH-SY5Y
cells over-expressing human α-syn or mutant A53T or A30P
showed increased generation of ROS that was greater in cells
expressing α-syn mutants. Furthermore, exposure of all three
α-syn-engineered cells to dopamine resulted in decreased cell
viability (Junn and Mouradian, 2002).
Mitochondrial dysfunction. Mitochondria are membranous
organelles that also have been proposed as cellular targets for
α-syn neurotoxicity. Release of cytochrome c from mitochondria
is a key event inducing apoptosis in many cells including neurons.
One study showed that both A53T mutant and WT α-syn were
localized at themitochondria in human neuroblastoma dopamin-
ergic SHSY cells and that overexpression of α-syn A53T or WT in
these cells caused the release of cytochrome c from mitochondria
(Parihar et al., 2008). The same phenomenon was observed with
the induction of A53T α-syn expression in PC12 cells, where the
increased release of cytochrome c from the mitochondria and its
accumulation in the cytosol was also associated with increased
caspase-3 and -9 activities over time [see Figure 3(3)] (Smith
et al., 2005).
Mitochondria are main cellular calcium stores and play a
crucial role for cellular calcium homeostasis. It is known that
alterations in cellular calcium levels contribute to apoptosis of DA
neurons in PD. The expression of α-syn A53T orWT is associated
with higher concentrations of mitochondrial Ca2+, and excess
Ca2+ initiates an apoptotic pathway. Thus, α-syn induces apop-
tosis via mitochondria-dependent pathways, including activation
of caspases (Parihar et al., 2008).
Another study showed that aggregated and un-aggregated
α-syn binds to mitochondrial membranes of human dopaminer-
gic neuroblastoma SHSY cells (Parihar et al., 2009). Significantly
higher mitochondrial ROS was observed in cells overexpress-
ing α-syn, known to cause mitochondrial and cellular damage.
The level of ROS in A53T α-syn expressing cells was higher
than in A30P and WT expressing cells, suggesting greater neu-
ronal toxicity of the A53Tmutant. In addition, the mitochondrial
membrane potential (ψ) was measured as an indicator of mito-
chondrial function. A decrease in ψ was observed in α-syn
overexpressing cells in which A53T expressing cells had the lowest
ψ. These findings suggest that the decreased ψ and conse-
quent mitochondrial dysfunction are more likely to be a result of
mitochondrial damage by elevated mitochondrial ROS and Ca2+
(Parihar et al., 2009).
ER stress. Cellular accumulation of misfolded proteins can lead to
chronic endoplasmic reticulum stress (ERS) and trigger an inte-
grated cellular response called unfolded protein response (UPR)
(Doyle et al., 2011) that protects cells from accumulation of
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toxic misfolded proteins. However, persistent ERS leads to the
activation of cell death cascade (Colla et al., 2012a).
A study found an increase in ER chaperones such as grp94,
grp78, and PDI (widely used markers of ERS/UPR activation)
in affected regions with α-syn pathology using a transgenic (Tg)
mouse model expressing human α-syn (WT or mutant). The
investigators identified a subset of phosphorylated α-syn reactiv-
ity that was localized on the ER membranes. The ER morphology
in these neurons was highly abnormal with severely dilated ER
cisternae, an ultrastructural indication of ER dysfunction in the
A53T α-syn Tgmice (Colla et al., 2012a). Another study examined
postmortem tissues of human PD patients and mouse cases of α-
synucleinopathy and found selective accumulation of toxic α-syn
oligomers within the ER/microsome compartment, supporting a
direct pathological link between α-syn oligomers and ER stress
in vivo (Colla et al., 2012b). The α-synucleinopathy and ER stress
in the Tgmice model was also associated with the increased cleav-
age of caspase-12 and other downstream caspases (Colla et al.,
2012a). The cleavage and activation of procaspase-12 is the hall-
mark of ER stress-induced apoptosis. In PC12 cells, the induction
of A53T expression and the activity of caspase-12 was also sig-
nificantly increased, suggesting that the expression of A53T α-syn
causes ER stress mediated apoptosis in vitro (Smith et al., 2005).
Membrane disruption and pore formation. Another vastly stud-
ied cellular toxicity pathway of α-syn is the permeabilization of
cellular membranes by oligomers (Stockl et al., 2013). As seen
in [Figure 3(2)], the oligomers might interfere with the normal
functions of cellular membranes and form pore-like structures,
resulting in abnormal calcium influx (or other ions) with conse-
quent neurodegeneration (Tsigelny et al., 2012).
Several studies indicate that α-syn oligomers are able to inter-
act with lipid membranes, increase the conductance and form a
pore complex in planar lipid bilayers (Kim et al., 2009; Schmidt
et al., 2012; Tosatto et al., 2012). The same effect was observed
in HEK293T cells over-expressing α-syn (Tsigelny et al., 2007).
It has been reported that mutant α-syn (A53T or A30P) causes
higher membrane permeability and induces the formation of
pores in the plasma membrane of SH-SY5Y cells, which allows
Ca2+ influx, and therefore plays an important role in cell degen-
eration (Furukawa et al., 2006). Similarly, a study by Feng et al.
(2010) in a dopaminergic-like cell model demonstrated that the
over-expression of WT α-syn caused the formation of oligomeric
α-syn pore-like structures. Using whole-cell patch-clamp record-
ings, an increase in membrane conductance was found indicating
the presence of opened membrane channels. These findings were
associated with a modest but significant time-dependent increase
in cell death and the authors hypothesized that pores formed
by α-syn would act as non-selective channels and contribute to
α-syn-induced toxicity (Feng et al., 2010).
According to molecular dynamic simulations done by Tsigelny
et al. (2012), α-syn monomers penetrate the membrane and
via attractive energies of intermolecular contact can develop
a ring structure (α-syn octamer). This assembly possesses an
intrinsic opening diameter of around 35Å in the middle of the
oligomer and an external diameter of 130Å. The investigators
observed that the accumulation of α-syn in neuronal membranes
altered cellular function. Neurons overexpressing α-syn displayed
increased permeability and this effect was more apparent in the
cells expressing A53T α-syn. Consistent with this increased per-
meability, neuronal cell cultures expressing either WT or A53T
α-syn displayed increased levels of intracellular calcium. In sum-
mary, these results suggest a model where penetration of mem-
branes by α-syn gives rise to the formation of annular pore-like
oligomeric structures with the ability to increase cell permeability
and calcium influx (Tsigelny et al., 2012).
CONCLUSIONS
Accumulation of misfolded proteins have been linked to the gen-
eration and propagation of neurodegenerative diseases such as PD
which is characterized by the degeneration and loss of DA neu-
rons in the SNpc that leads to the main motor symptoms of the
disease, as well as the degeneration of other non-dopaminergic
brain regions. Protein inclusions called Lewy Bodies of which the
main component is alpha-synuclein, a pre-synaptic unfolded pro-
tein that can adopt different conformations and form aggregates,
are found in the cytoplasm of neurons. Mutations in the gene
that encodes α-syn (A53T, A30P or E46K) result in proteins with
a high tendency to misfold and form fibrillar aggregates rich in
β-sheet structure. These mutations highlight the relevance and
involvement of α-syn in the onset of PD cases.
Throughout this review we have referred to two important
properties of alpha-synuclein. First, the ability of this protein
to move from neuron to neuron, propagating the pathology by
using a seeding/nucleation mechanism similar to prion proteins
where misfolded α-syn recruits endogenous native α-syn to mis-
fold and aggregate. Interestingly, the α-syn transmission occurs
through different mechanisms such as exocytosis/endocytosis,
by exosomes or directly by penetrating the plasma membrane.
Second, the ability of α-syn to cause cellular toxicity, mainly in
its oligomeric state. Studies have reported that α-syn oligomers
affect several cellular organelles by binding to them and impairing
their physiological functions. The most investigated mechanisms
of WT and mutated α-syn toxicity include proteasome inhibi-
tion, oxidative stress, endoplasmic reticulum stress that leads
to the activation of caspases, mitochondrial dysfunction and
the eventual release of cytochrome c that also activates caspase
pathways. One relevant mechanism of α-syn cytotoxicity is the
formation of pore-like structures in different kinds of cellular
membranes that act as a non-selective channel allowing the pas-
sage of small molecules and cations like Ca2+ that are well known
to be involved in neurodegeneration. A recent study demon-
strated that Aβ also forms pore-like structures and allows the
entry of molecules such as Ca2+ that could cause neurotoxicity
in brains of AD patients (Sepulveda et al., 2014). Table 1 shows
the similarities and differences between α-syn and Aβ peptide.
The reason why α-syn is able to propagate and cause toxic-
ity is not fully understood, but may rely on its conformational
plasticity which allows the protein to adopt a secondary structure
under different conditions. A study by Danzer et al. (2007) iden-
tified diverse types of α-syn oligomers using distinct preparation
protocols. One oligomer type increased the intracellular calcium
level, provoked increase membrane permeability and triggered
cell death. Other oligomers were able to enter cells directly and
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Table 1 | Comparison between α-synuclein and β-amyloid characteristics.
α-synuclein B-amyloid References
Amino acids 140 42 Masters et al., 1985; Bisaglia et al., 2009
Accumulation Intracellular Lewy body Extracellular Senile plaques Soto, 2003
Wide membrane association Yes Yes Sepulveda et al., 2010; Pacheco et al., 2015
Pore formation Yes Yes Feng et al., 2010; Sepulveda et al., 2010
Estimated inner pore diameter 35Å 15-27Å Jang et al., 2007; Tsigelny et al., 2012
Influx of glucose analog (6-NBDG) Yes Yes Sepulveda et al., 2014; Pacheco et al., 2015
Calcium influx Yes Yes Tsigelny et al., 2012; Sepulveda et al., 2014
Most toxic specie Oligomers Oligomers Aguayo et al., 2009; Stockl et al., 2013
Synaptic toxicity Late ? Vesicular depletion Parodi et al., 2010; Pacheco et al., 2015
Cellular transmission Yes ? Luk et al., 2012a,b
seed intracellular α-syn aggregation. The conclusion of this study
was that depending on the brain milieu conditions, heteroge-
neous populations of α-syn oligomers could be formed that
have different biophysical properties and cellular effects (Danzer
et al., 2007). Therefore, some important questions would be, what
makes α-syn able to form different aggregated structures that dif-
fer in number of monomers and cellular effects? Why does α-syn
use a transmission mechanism or cause a toxic effect in one type
of cell, and in other cells uses another transmission mechanism
and causes other toxic effects? These are questions that would be
relevant to discuss in further studies. The properties of α-syn dis-
cussed in this review could explain why PD is a progressive and
irreversible disease. However, it is possible that α-syn is not the
only agent participating in the development and progression of
PD, but it does indeed have a strong influence on the complexity
of developing an effective therapy for PD.
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